#IBRX

Thiard News@F4F

@newsen.bsky.social

3 minutes ago

ImmunityBio Class Action Lawsuit: Join the Fight Against Investor Losses Investors have a unique opportunity to lead the ImmunityBio class action lawsuit, addressing recent substantial losses tied to alleged misleading statements.

ImmunityBio Class Action Lawsuit: Join the Fight Against Investor Losses #United_States #San_Diego #Class_Action #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 day ago

Investors Invited to Participate in ImmunityBio, Inc. Securities Fraud Class Action Lawsuit Investors in ImmunityBio, Inc. can join a class action lawsuit initiated by the Rosen Law Firm. Important deadlines approaching for plaintiffs.

Investors Invited to Participate in ImmunityBio, Inc. Securities Fraud Class Action Lawsuit #USA #New_York #Rosen_Law #ImmunityBio #IBRX

StockTitan

@stocktitan.net

2 days ago

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance ImmunityBio (NASDAQ: IBRX) submitted a comprehensive response to FDA OPDP on April 6, 2026, addressing concerns about a podcast and a referenced television advertisement for ANKTIVA.The company removed the podcast from its site, requested third‑party removal, confirmed the TV ad was never broadcast, and outlined enhanced promotional review, executive training, and external regulatory oversight.

#IBRX ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

www.stocktitan.net/news/IBRX/immunity-bio-a...

Thiard News@F4F

@newsen.bsky.social

2 days ago

Opportunities for IBRX Investors to Lead Class Action Against ImmunityBio, Inc. Investors in ImmunityBio, Inc. have a chance to engage in a class action lawsuit concerning alleged securities fraud. Schall Law Firm is handling the case, encouraging affected shareholders to join.

Opportunities for IBRX Investors to Lead Class Action Against ImmunityBio, Inc. #United_States #Los_Angeles #Schall_Law_Firm #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

2 days ago

ImmunityBio Faces Class Action Lawsuit for Securities Violations Amid Investor Concerns ImmunityBio, Inc. is embroiled in a class action lawsuit for allegedly violating securities laws. Investors urged to join.

ImmunityBio Faces Class Action Lawsuit for Securities Violations Amid Investor Concerns #United_States #Los_Angeles #DJS_Law_Group #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

4 days ago

ImmunityBio Investors Alert: Class Action Deadline Approaches for Shareholders Attention ImmunityBio investors: A securities class action deadline looms on May 26, 2026. Don't miss your chance to seek justice and compensation.

ImmunityBio Investors Alert: Class Action Deadline Approaches for Shareholders #United_States #New_York #Faruqi_&_Faruqi #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

4 days ago

ImmunityBio Shareholders Urged to Act Quickly on Class Action Lawsuit by ClaimsFiler Investors affected by ImmunityBio's alleged misinformation have a deadline approaching for filing lead plaintiff applications. Act by May 26, 2026.

ImmunityBio Shareholders Urged to Act Quickly on Class Action Lawsuit by ClaimsFiler #United_States #New_Orleans #ClaimsFiler #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

5 days ago

ImmunityBio, Inc. Faces Class Action Lawsuit; Investors Must Act by May 2026 Investors in ImmunityBio, Inc. must file for lead plaintiff status in a class action lawsuit by May 26, 2026, regarding alleged securities fraud.

ImmunityBio, Inc. Faces Class Action Lawsuit; Investors Must Act by May 2026 #United_States #Radnor #ImmunityBio #IBRX #Anktiva

Thiard News@F4F

@newsen.bsky.social

5 days ago

ImmunityBio, Inc. Faces Class Action Lawsuit Over Securities Violations ImmunityBio, Inc. is currently under a class action lawsuit due to alleged violations of securities laws, impacting many investors. Find out more.

ImmunityBio, Inc. Faces Class Action Lawsuit Over Securities Violations #USA #Los_Angeles #DJS_Law_Group #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

5 days ago

IBRX Investors Have Chance to Lead Securities Fraud Case Against ImmunityBio, Inc. Investors from ImmunityBio, Inc. have the opportunity to join a class action due to alleged securities fraud violations. Act now before May 26, 2026.

IBRX Investors Have Chance to Lead Securities Fraud Case Against ImmunityBio, Inc. #USA #Los_Angeles #Schall_Law_Firm #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

6 days ago

IBRX Investors Encouraged to Join Class Action Against ImmunityBio for Securities Fraud Rosen Law Firm has initiated a class action lawsuit for ImmunityBio investors over securities fraud, urging timely participation for potential compensation.

IBRX Investors Encouraged to Join Class Action Against ImmunityBio for Securities Fraud #USA #New_York #Rosen_Law_Firm #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Class Action Lawsuit Filed Against ImmunityBio for Securities Fraud: What Investors Should Know A class action lawsuit against ImmunityBio, Inc. has been initiated, notifying investors of potential claims due to alleged FDA violations. Learn more.

Class Action Lawsuit Filed Against ImmunityBio for Securities Fraud: What Investors Should Know #United_States #New_York #Class_Action #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

IBRX Investors Encouraged to Join Class Action Against ImmunityBio for Securities Fraud Investors in ImmunityBio, Inc. have an opportunity to join a class action lawsuit for securities fraud. The Schall Law Firm is seeking shareholders to recover losses.

IBRX Investors Encouraged to Join Class Action Against ImmunityBio for Securities Fraud #USA #Los_Angeles #Securities_Fraud #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

ImmunityBio Investors Have Chance to Lead Class Action Lawsuit Following Major Stock Losses Investors in ImmunityBio, Inc. with significant losses during the recent class period have the opportunity to lead a major class action lawsuit. Act before the deadline!

ImmunityBio Investors Have Chance to Lead Class Action Lawsuit Following Major Stock Losses #USA #San_Diego #Class_Action #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

ImmunityBio Inc. Shareholders Urged to Act Before May 26 Deadline ImmunityBio, Inc. shareholders are urged to register for a securities class action lawsuit before the lead plaintiff deadline on May 26, 2026. Take action now!

ImmunityBio Inc. Shareholders Urged to Act Before May 26 Deadline #United_States #New_York #Gross_Law_Firm #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline Investors of ImmunityBio are reminded about the upcoming deadline for a class action lawsuit on May 26, 2026, regarding potential financial claims.

ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline #United_States #New_York #Faruqi_&_Faruqi #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit Rosen Law Firm has initiated a class action lawsuit on behalf of ImmunityBio investors. Affected shareholders may be eligible for compensation. Act before the deadline!

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit #USA #New_York #Rosen_Law_Firm #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit Investors of ImmunityBio, Inc. facing significant losses have a valuable opportunity to become the lead plaintiff in a class action lawsuit against the company.

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit #USA #San_Diego #Class_Action #ImmunityBio #IBRX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors Investors in ImmunityBio, Inc. are urged to contact Pomerantz LLP regarding potential claims of securities fraud and unlawful practices.

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors #United_States #New_York #Pomerantz #ImmunityBio #IBRX

InsiderFinance

@insiderfinance.com

2 weeks ago

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MO 11.1x
2. #LOVE 7.2x
3. #GFS 5.7x
4. #CHWY 4.8x
5. #IBRX 4.5x

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

2 weeks ago

💥 Institutions trading #options with high urgency! PM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

PM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 102.7K
2. #TSLA 79.3K
3. #AAL 36.7K
4. #MU 31.7K
5. #IBRX 30.8K

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

2 weeks ago

📈 Heavy institution #Equity #optionsvolume! AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥 1

📈 Heavy institution #Equity #optionsvolume!

AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TSLA 60.0K
2. #NVDA 51.4K
3. #IBRX 34.8K
4. #AAL 22.2K
5. #MARA 18.8K

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

2 weeks ago

💥 Institutions trading #options with high urgency! AM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

AM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TSLA 57.6K
2. #NVDA 42.9K
3. #IBRX 29.8K
4. #AAL 22.2K
5. #MARA 18.8K

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

2 weeks ago

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors ImmunityBio (NASDAQ: IBRX) announced regulatory approval in Macau SAR, China for ANKTIVA (nogapendekin alfa inbakicept-pmln) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary tumors.The authorization used a reliance-based review referencing prior FDA and EMA decisions, marks ANKTIVA’s first approval in Asia, and supports the company’s ongoing global expansion across 34 countries and territories. The company cited QUILT 3.032 data published in NEJM Evidence and The Journal of Urology demonstrating durable responses.

#IBRX ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

www.stocktitan.net/news/IBRX/immunity-bio-a...

@averagepenny.bsky.social

2 weeks ago

Stocks Under $10 to Watch in 2026: IBRX, VTIX, NDRA, SMX — Emerging Themes Across Biotech, XR, Diagnostics, and AI Supply Chains Getting your Trinity Audio player ready... As capital rotation intensifies across micro- and small-cap equities in 2026, a new wave of sub-$10 stocks is gaining traction among investors seeking exposu...

Stocks Under $10 to Watch in 2026: #IBRX, #VTIX, #NDRA, #SMX — Emerging Themes Across Biotech, XR, Diagnostics, and AI Supply Chains

thestreetreports.com/stocks-under...

StockTitan

@stocktitan.net

3 weeks ago

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors ImmunityBio (NASDAQ: IBRX) reported successful validation of large‑scale manufacturing and cryo‑banking for autologous memory cytokine‑enhanced NK (M‑ceNK) cells.Key metrics: single apheresis yields up to 5×10⁹ NK cells, providing 8–10 doses; finished doses available within 12 days; programs enrolled 74 subjects with manufacturing datasets from 64 apheresis collections. Phase 1 (QUILT‑3.076) combined M‑ceNK with ANKTIVA® in 10 patients with no Grade 4/5 TRAEs reported. Cryopreserved M‑ceNK retained tumor cytotoxicity across multiple histologies.

#IBRX ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

www.stocktitan.net/news/IBRX/immunity-bio-a...

InsiderFinance

@insiderfinance.com

3 weeks ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PATH, #ISPR, #IBRX, #TSSI, #APLD

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

3 weeks ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LUNR, #CVNA, #IBRX, #PATH, #APLD

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

4 weeks ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AXTI, #VRT, #CRML, #IBRX, #APLD

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

1 month ago

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 ImmunityBio (NASDAQ: IBRX) will host a live conference call at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, March 3, 2026 to provide a business update and review financial results for the year ended December 31, 2025.According to the company, the call will cover progress across its clinical trial pipeline. Interested parties can join via the investor relations website or by phone; a replay will be posted and available for at least 90 days.

#IBRX ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

www.stocktitan.net/news/IBRX/immunity-bio-t...